neuroscience News
-
IOS Press Continues Impact Factor Growth
Amsterdam, the Netherlands – IOS Press, an independent international publisher of English-language scientific, technical and medical (STM) journals and books, has announced that its journal Impact Factors continue to increase, according to the 2013 Journal Citation Reports® (JCR) released by Thomson Reuters © 2014. Thirty IOS Press journals are currently included in the JCR, ...
By IOS Press
-
Inscopix Expands Strategic Partnership with GRINTECH to Become Exclusive Global Supplier of GRIN lenses
Inscopix, Inc., a neuroscience company helping decode the brain for tomorrow’s treatments, announced that it is expanding its strategic supplier partnership with leading gradient index (GRIN) lens manufacturer GRINTECH GmbH to be the sole exclusive seller of GRIN lenses for neuroscience research applications. Inscopix offers innovative miniature-microscope (miniscope) based imaging ...
-
Inscopix Launches Cloud-Based Platform for Data Management and Analysis to Advance Neurotherapeutic Development
Inscopix, Inc., a neuroscience company helping decode the brain for tomorrow’s treatments, announced that it has launched IDEAS, a cloud-based platform for enterprisesthat supports the integration, organization, management and sharing of neuroscience research, data and methods to accelerate development of the next-generation of neurotherapeutics. Today, neuroscience groups frequently use ...
-
Newton Howard at TEDx – The Human Brain
The evolution of humanity is based on the evolution of the human brain. What are the next steps in our evolutionary process and what is the role that technology will play? Dr. Howard leads the Laboratory of Computational Neuroscience in Oxford and the Laboratory of Synthetic Intelligence at MIT. He is a founding member of the Committee of two NGOs: the Howard Brain Sciences Foundation, which ...
By ni2o, Inc.
-
Vybion announces the addition of Drs. Matthew DeLisa, William Ball and Andrew Norman to its Scientific Advisory Board
Vybion announces the addition of Drs. Matthew DeLisa, William Ball and Andrew Norman to its Scientific Advisory Board. Matthew DeLisa, Ph.D. is on the faculty of Cornell University in the Department of Chemical and Molecular Engineering and the inventor of ProCode. DeLisa's research group combines protein engineering with genetic and molecular biology approaches to address fundamental issues ...
By Vybion
-
Enveric Biosciences to Host Fireside Chat with Dr. Bob Dagher, Chief Medical Officer, on May 17th at 10:00 a.m. ET
Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that it will host a virtual fireside chat with its Chief Medical Officer, Dr. Bob Dagher, on Tuesday, May 17, 2022 at 10:00 a.m. EDT. Dr. Bob Dagher has over 20 years ...
-
AIVITA Biomedical Appoints Dr. H. Christian Fibiger to its Board of Directors
IRVINE, Calif. – Apr. 5, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced the appointment of distinguished neuroscientist and industry specialist H. Christian Fibiger, Ph.D. to its board of directors. Dr. Fibiger served as vice president and global head of neuroscience at Amgen, the world’s largest ...
-
Publications by our customers - current trends
We took a look at the number of publications created using BESA software. And we need to conclude: the trend is positive! Each year, more publications get generated where BESA software is used. In particular, over the last couple of years BESA Statistics and BESA Connectivity featured much more frequently than before, reflecting the trend to analyze brain connectivity, and to present ...
By BESA GmbH
-
Artificial Intelligence Expert Neil Sahota Joins Evoke Neuroscience Executive Advisory Board
NEWPORT BEACH, CA, USA, May 7, 2020 /EINPresswire.com/ — Evoke Neuroscience announced today that IBM Master Inventor, United Nations Artificial Intelligence (AI) Subject Matter Expert, and UC Irvine Professor Neil Sahota has joined the company’s executive advisory board. For the past 20 years, Neil has worked with Global Fortune 500 companies and world government leaders to foster ...
-
Relmada Therapeutics to Participate in Fireside Chats at Two Upcoming Healthcare Events
Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in fireside chats at Needham & Company's 1st Annual Neuroscience Forum and Oppenheimer's 32nd Annual Healthcare Conference, taking ...
-
BioXcel Therapeutics to Present at Bank of America 2022 Biotech SMID Cap Conference
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, and Matt Wiley, Chief Commercial Officer, will participate in a virtual fireside chat at the Bank of America 2022 Biotech SMID Cap ...
-
BioXcel Therapeutics to Participate at the Canaccord Genuity 42nd Annual Growth Conference
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, and Matt Wiley, Chief Commercial Officer, will participate in a fireside chat at the Canaccord Genuity 42nd Annual ...
-
Sage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for Zuranolone
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced that the companies will host a joint investor webcast to discuss the planned commercialization approach and opportunity for their investigational product, zuranolone, on Tuesday, December 6 at 8:00 a.m. ET. Zuranolone is being evaluated as a potential rapid-acting, once-daily, oral two-week treatment for major ...
-
STALICLA strengthens pipeline to advance precision medicine for Autism Spectrum Disorders
STALICLA SA, a precision neuroscience clinical stage biotech advancing the first precision medicine platform for patients with Neurodevelopmental Disorders, has in-licensed SFX-01 from Evgen Pharma plc in neurodevelopmental disorders and schizophrenia. The first indication targets a biologically characterised subgroup of patients with Autism Spectrum Disorder (ASD) STALICLA's unique approach ...
By STALICLA
-
Focussing on Australia`s second biggest killer
The cluster will conduct the START (Stroke, imaging, pRevention and Treatment) cohort study of stroke which is designed to integrate imaging and biomarker analysis to identify patients at risk of stroke. Those strategies will then be used to develop preventative measures for those patients. The START Cohort will collect and analyse information derived from brain imaging and blood samples taken ...
-
Metlife foundation announces major awards to scientists for research in alzheimer`s disease
The 25th anniversary presentation of the MetLife Foundation Awards for Medical Research in Alzheimer's Disease (AD) was held today honoring two noted researchers, Randy L. Buckner, Ph.D., professor of Psychology and of Neuroscience at Harvard University and Howard Hughes Medical Institute Investigator, and Marcus E. Raichle, M.D., professor of radiology and neurology at Washington University ...
-
Neurolief Announces Exclusive Licensing Agreement with NeuroFront for Development and Commercialization of Relivion in Greater China and South Korea
Neurolief, an Israel-based company pioneering neuromodulation for the treatment of chronic neurological and neuropsychiatric disorders, and NeuroFront, a clinical stage biotech company focusing on innovative neuroscience therapies, jointly announced an exclusive licensing agreement for NeuroFront to develop and commercialize Relivion, non-invasive medical devices for the treatment of migraine and ...
-
Alkahest Announces Multiple Presentations at the Society for Neuroscience Annual Meeting
Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today announced upcoming presentations at the Society for Neuroscience (SFN) 49th Annual Meeting being held October 19 – October 23, 2019 at the McCormick Place Convention Center in Chicago. The Company will present data from recent studies demonstrating the ...
-
TikoMed AB reports positive phase II clinical data for the treatment of Amyothropic Lateral Sclerosis in data published by PLOS ONE
A new study with TikoMed’s platform lead clinical drug candidate ILB®, provides positive safety and tolerability results and the first clinical evidence of encouraging clinical efficacy of ILB® in the treatment of Amyotrophic Lateral Sclerosis (ALS). The study was published in PLOS ONE today. In a phase II study of ILB administered to patients with ALS for five weeks, the ...
By TIKOMED AB
-
BioXcel Therapeutics Announces Formation of OnkosXcel Therapeutics to Develop Medicines Focused in Oncology
OnkosXcel, a Company subsidiary, to utilize proprietary AI-powered platform to progress therapies to address difficult-to-treat cancers with high unmet need New structure to unlock growth opportunities and maximize value of neuroscience and immuno-oncology franchises Lead pipeline asset, BXCL701, has shown clinical proof-of-concept in aggressive forms of prostate cancer and is currently in ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you